乳腺癌中的GD2:一个潜在的生物标志物和治疗目标
1The London Breast Institute, Princess Grace Hospital, London, U.K. Kefah.Mokbel@hcahealthcare.co.uk.
Cancer genomics & proteomics
|October 28, 2024
概括
在乳腺癌中,disialoganglioside GD2 过度表达,促进瘤生长和转移. 用单克隆抗体等疗法向GD2提供了有前途的治疗策略,可以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 滴立方格化物GD2通常局限于特定的组织,但在许多癌症中过度表达.
- 这种过度表达将GD2定位为具有诊断和治疗潜力的瘤相关抗原.
- GD2在癌细胞粘附,增殖和转移中发挥作用.
研究的目的:
- 审查GD2合成途径及其在癌症,特别是乳腺癌中的作用.
- 突出GD2在乳腺癌中的过度表达及其与攻击性特征的相关性.
- 讨论针对GD2的治疗策略及其临床影响.
主要方法:
- 关于GD2合成,癌症中的功能和治疗向的文献综述.
- 对乳腺癌样本中GD2表达的临床数据的分析.
- 对GD2向疗法的临床前和临床研究的审查.
主要成果:
- 在大多数乳腺癌细胞和乳腺癌干细胞上,GD2的过度表达与上皮-介质细胞过渡有关.
- 在35-70%的乳腺癌样本中,GD2表达升高,特别是三阴性乳腺癌 (TNBC).
- GD2过度表达与瘤的攻击性特征和更差的预后相关.
结论:
- GD2是乳腺癌发病的一个关键因素,提供了重要的治疗机会.
- 单克隆抗体,CAR T细胞疗法,GD3合成酶抑制和疫苗是有希望的GD2向治疗方法.
- 需要进一步的临床试验来探索涉及GD2向和标准乳腺癌治疗的组合疗法.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


